ABCL - Abcellera Biologics - Stock Forecast

Healthcare - Sector

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

ABCL is currently covered by 5 analysts with an average price target of $15.61. This is a potential upside of $10.69 (217.28%) from yesterday's end of day stock price of $4.92.

Abcellera Biologics 's activity chart (see below) currently has 39 price targets and 44 ratings on display. The stock rating distribution of ABCL is 78.95% BUY and 21.05% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 18.88% with an average time for these price targets to be met of 87.29 days.

Highest price target for ABCL is $10, Lowest price target is $5, average price target is $13.

Most recent stock forecast was given by SCOTT SCHOENHAUS from KEYBANK on 14-Jul-2025. First documented stock forecast 05-Jan-2021.

Best performing analysts who are covering ABCL - Abcellera Biologics :

Puneet Souda Scott Schoenhaus Do Kim Tiago Fauth Gary Nachman Andrea Tan Robert Wasserman

Currently out of the existing stock ratings of ABCL, 15 are a BUY (78.95%), 4 are a HOLD (21.05%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Scott Schoenhaus (KEYBANK)

Buy

$10

$4.89 (95.69%)

14 days ago
(14-Jul-2025)

3/7 (42.86%)

$5.76 (135.85%)

217

Please subscribe to see the analyst performance score

Robert Wasserman (BENCHMARK)

Hold

4 months 25 days ago
(03-Mar-2025)

0/2 (0%)

$6.55 (120.18%)

Please subscribe to see the analyst performance score

Gary Nachman (RAYMOND JAMES)

Buy

$-0.11 (-2.15%)

$22

8 months 23 days ago
(05-Nov-2024)

1/4 (25%)

$2.28 (83.82%)

258

Please subscribe to see the analyst performance score

Andrea Tan (GOLDMAN SACHS)

Buy

$24

$18.89 (369.67%)

$30

1 years 11 months 24 days ago
(04-Aug-2023)

0/2 (0%)

$17.96 (297.35%)

Please subscribe to see the analyst performance score

Tiago Fauth (WELLS FARGO)

Buy

$28

$22.89 (447.95%)

$34

2 years 2 months 23 days ago
(05-May-2023)

1/6 (16.67%)

$22.01 (367.45%)

Please subscribe to see the analyst performance score

Show more analysts

Load Price Targets and Ratings Chart

To gain access for the analyst/ stock price target chart please use a computer

What is ABCL (Abcellera Biologics ) average time for price targets to be met?

On average it took 87.29 days on average for the stock forecasts to be realized with a an average price target met ratio 18.88

Which analyst has the current highest performing score on ABCL (Abcellera Biologics ) with a proven track record?

PUNEET SOUDA

Which analyst has the current lower performing score on ABCL (Abcellera Biologics ) with a proven track record?

ROBERT WASSERMAN

Which analyst has the most public recommendations on ABCL (Abcellera Biologics )?

Puneet Souda works at LEERINK and has 19 price targets and 10 ratings on ABCL

Which analyst is the currently most bullish on ABCL (Abcellera Biologics )?

Tiago Fauth with highest potential upside - $22.89

Which analyst is the currently most reserved on ABCL (Abcellera Biologics )?

Gary Nachman with lowest potential downside - -$0.11

Abcellera Biologics in the News

Abcellera Biologics stock hits 52-week high at 4.09 USD

Abcellera Biologics Inc. (ABCL) stock reached a 52-week high, trading at 4.09 USD. This milestone comes as the company experiences a significant 1-year change, with its stock appreciating by 46%. According to InvestingPro data, technical indicators suggest the stock is currently overbought, with strong momentum showing returns of 11% in the past week alone. The...

Truist Financial Lowers PT on AbCellera Biologics (ABCL) to $10 From $28, Keeps a Buy Rating

AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the 13 Stocks Under $5 With High Upside Potential. On May 16, Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on AbCellera Biologics Inc. (NASDAQ:ABCL), lowering the price target to $10 from $28.Is AbCellera Biologics Inc. (ABCL) the Best Canadian Penny Stock to Invest in Now? A...